8-K: Qualigen Appoints Kevi Chen to Board

Qualigen Therapeutics, Inc. announced the appointment of Kevi Chen as an independent member of its Board of Directors, effective September 26, 2025.

Summary

• Qualigen Therapeutics, Inc. appointed Kevi Chen as an independent member of its Board of Directors.
• The appointment was effective immediately on September 26, 2025.
• Mr. Chen, 47, brings extensive experience as Chief Economist and CIO of Horizon Financial.
• He currently serves on the boards of CurrenC Group, Australian Oilseeds Investments, Scage Future (all Nasdaq-listed), and Capitan Investment Ltd. (Toronto Stock Exchange-listed).
• His background includes senior roles as Senior Portfolio Manager at Credit Agricole/Amundi Asset Management, Director of Asset Allocation at Morgan Stanley, and Manager at China Development Bank.
• Mr. Chen holds a PhD in Finance from the University of Lausanne, a Masters in Finance from Tilburg University, and a B.A. in Economics from Renmin University of China.
• As of the filing date, Mr. Chen has not been appointed to any Board committees.

Sentiment

Score: 7

Explanation: The appointment of a highly qualified and experienced independent director is a positive step for corporate governance, enhancing the board's expertise and oversight capabilities. While not directly impacting financial performance, it signals a commitment to strong leadership.

Positives

• The appointment of a highly experienced independent director, Kevi Chen, strengthens the Board's expertise in finance, economics, and investment.
• Mr. Chen's current and past board memberships across multiple public companies (Nasdaq, NYSE, TSX) indicate a strong understanding of corporate governance and public market dynamics.
• His academic background, including a PhD in Finance and roles as an Adjunct Associate Professor at NYU, adds significant intellectual capital to the Board.
• His diverse professional experience, from asset management to investment banking and development banking, provides a broad perspective beneficial for strategic oversight.

Future Outlook

The filing does not provide specific forward-looking statements or financial guidance, focusing solely on the board appointment.

Industry Context

The appointment of an independent director with extensive financial and governance experience is a common practice for publicly traded companies, particularly in the biotechnology sector, to enhance oversight and strategic guidance. This move aligns Qualigen with broader industry trends emphasizing robust corporate governance.

Comparison to Industry Standards

• Adding an independent director with a strong financial and academic background, like Kevi Chen, aligns with best practices for corporate governance in the biotechnology and pharmaceutical industries.
• Companies such as Gilead Sciences or Amgen frequently appoint directors with diverse expertise in finance, science, and business to their boards to ensure comprehensive oversight and strategic direction.
• Mr. Chen's experience on other Nasdaq-listed boards (e.g., CurrenC Group, Australian Oilseeds Investments, Scage Future) demonstrates a level of public company governance experience comparable to directors at well-established industry peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for improved corporate governance and strategic decision-making due to enhanced board expertise.
• Management: Benefits from additional guidance and oversight from an experienced independent director.

Next Steps

• Kevi Chen may be appointed to various committees of the Board of Directors in the future.

Key Dates

Recommendation

The appointment of a highly qualified independent director like Kevi Chen is a positive development for Qualigen's corporate governance, signaling a commitment to strong oversight and strategic expertise. However, this event alone does not directly impact the company's operational or financial performance in the short term to warrant a 'buy' or 'sell' recommendation. It's a foundational improvement that supports long-term stability and investor confidence, hence a 'hold' is appropriate for existing investors, while new investors should await further operational catalysts.

Keywords

Qualigen Therapeutics, QLGN, Board of Directors, Kevi Chen, Independent Director, Corporate Governance, Biotechnology, Pharmaceuticals, SEC Filing, 8-K